Data Sheet (Cat.No.T7773)

TargetMol

DPPC

Chemical Properties



CAS No. : 63-89-8

Formula: C40H80NO8P

Molecular Weight: 734.04

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	DPPC (129Y83) is a zwitterionic glycerophospholipid frequently utilized in the creation of lipid monolayers, bilayers, and liposomes.
Targets(IC50)	Endogenous Metabolite,Liposome
In vivo	Incorporation of glycosphingolipid antigens into DPPC-containing liposomes increases the immunogenicity of the antigens in mice[1]

Solubility Information

Solubility	DMSO: Insoluble, H2O: Insoluble, Ethanol: 100 mg/mL (136.23 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% EtOH+90% Corn Oil: 3.3 mg/mL (4.5 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.3623 mL	6.8116 mL	13.6232 mL
5 mM	0.2725 mL	1.3623 mL	2.7246 mL
10 mM	0.1362 mL	0.6812 mL	1.3623 mL
50 mM	0.0272 mL	0.1362 mL	0.2725 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Uemura A , Watarai S , Iwasaki T , et al. Induction of Immune Responses against Glycosphingolipid Antigens: Comparison of Antibody Responses in Mice Immunized with Antigen Associated with Liposomes Prepared from Various Phospholipids[J]. Journal of Veterinary Medical Science, 2005, 67(12):1197-1201.
Sakita K M, Vendramini F A V R, Svidzinski T I E, et al.Structure-based drug design of multi-targeting inhibitors of human pathogen fungi.Journal of Molecular Structure.2023: 135693.
Miller, Andrew D . Delivery of RNAi therapeutics: work in progress[J]. Expert Review of Medical Devices, 2013, 10(6): 781-811.